Evidence map›Paper›PMID 24613728›Full record

ReviewSeminars in immunology2014

The TNF family in T cell differentiation and function--unanswered questions and future directions.

Michael Croft

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 114 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Novel heterozygous mutations ofBlood science (Baltimore, Md.) · 2024
    Article
  8. Article
  9. Article
  10. Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  11. Diagnosis ofBiomedicines · 2022
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Combination blockade of OX40L and CD30L inhibits allergen-driven memory TThe Journal of allergy and clinical immunology · 2021
    Article
  17. Review
  18. New Biomarkers ofInternational journal of environmental research and public health · 2021
    Article
  19. Taking T-Cell Oncotherapy Off-the-Shelf.Trends in immunology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Michael CroftDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, United States. Electronic address: mick@lji.org.
La Jolla Institute for Immunology · US

Funding

TRM and airway inflammation and remodelingU19AI070535 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2006 to 2025
$34.2M
Treg stability in viral infection and autoimmunityP01AI089624 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PETERS, BJOERN · 2010 to 2014
$10.1M
The Molecular Basis of OX40 on CD4 T CellsR01AI049453 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2003 to 2012
$3.9M
Regulation of T Cell Tolerance by OX40R01CA091837 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2002 to 2012
$2.5M
TNF Family Members and Control of Fibrotic DiseaseR21AI100905 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2012 to 2013
$465k
NCI NIH HHS CA91837NCI NIH HHS R01 CA091837NIAID NIH HHS AI070535NIAID NIH HHS AI089624NIAID NIH HHS AI100905NIAID NIH HHS AI49453NIAID NIH HHS P01 AI089624NIAID NIH HHS R01 AI049453NIAID NIH HHS R21 AI100905NIAID NIH HHS U19 AI070535
6 · The paper itself

Abstract

Proteins in the TNF/TNFR superfamily are recognized as major regulators of the activity of conventional CD4 and CD8 T cells, and also of regulatory T cells (Treg). Stimulatory molecules such as OX40, CD27, GITR, DR3, CD30, 4-1BB, TACI, and TNFR2 can promote division and survival in T cells, enhance effector activity including cytokine production, and drive the generation of T cell memory. They also display the capacity to block the development of inducible Treg cells or inhibit suppressive activity in Treg cells. Additionally, molecules such as Fas, TNFR1, and TRAILR promote apoptotic death in T cells and generally limit T cell activity. Although our knowledge of these proteins is quite good at this point in time, there are still many unknowns regarding their function, their expression patterns, and the involvement of these different molecules at various stages of the T cell response that occurs in autoimmunity, cancer, infectious disease, and during vaccination. Importantly, it is still unresolved how similar or dissimilar each of these receptors are to one another, the extent to which cooperation occurs between family members, and whether alternate TNF-TNFR interactions induce qualitatively different cellular responses. All of the molecules are attractive targets for immunotherapy of human disease, but it is not yet clear how to differentiate between them and make an informed decision as to whether any one protein may be the preferred focus of clinical development for a given specific disease indication. This review will highlight unanswered questions related to these molecules and the biology of T cells, and describe possible future directions for research in this area. Expanding our knowledge of how the TNF/TNFR family control T cells will undoubtedly help fulfill the promise of these molecules for providing efficacious clinical therapy of immune system disease.

Indexed as

AnimalsCell DifferentiationHumansImmunologic MemoryT-LymphocytesTumor Necrosis FactorsTumor Necrosis Factors4-1BBCD27GITRHVEMOX40TNFR2

Identifiers

PMID24613728
PMCPMC4099277
OpenAlexW1972114621

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.